Medical Cannabis Technology Company Signs Deals in Canada and U.S.
November 1st, 2017
In a deal expected to disrupt the Canadian market, Resolve Digital Health Inc. (“Resolve”), a Canadian developer of intelligent medical cannabis delivery devices, has concluded an exclusive agreement with Aphria Inc. (“Aphria”), one of Canada’s largest licensed producers of medical cannabis.
Under the agreement, Aphria will provide cannabis products to fill Resolve’s proprietary delivery pods and cartridges for sale to the Canadian medical cannabis market.
Rob Adelson, CEO of Resolve said: “This agreement allows Resolve to take a significant step towards launching the first of our Breeze Smart InhalersTM domestically. Both organizations have impressive growth trajectories, and combining Resolve’s innovative technology with Aphria’s high-quality medical cannabis will allow us to disrupt the Canadian market.”
Breeze Smart Inhalers use machine-learning algorithms to provide patients with the dosing and strain selection most appropriate to their medical condition. The device captures data on medical conditions, prescriptions, family history, lifestyle, and effectiveness per dose, and uses that data to monitor treatment efficacy and continuously improve the medical cannabis experience for patients.
Vic Neufeld, CEO of Aphria and Chairman of the Board for Liberty Health Sciences Inc. (“Liberty”), said: “Aphria is delighted to partner with Resolve in Canada. This agreement is consistent with both companies’ commitment to leading in the space, and to bringing safe and effective cannabis products as part of a holistic medical cannabis ecosystem for Canadian patients.”
In the US, medical cannabis sales are projected to grow from $4.7 billion in 2016 to $13.3 billion in 2020.1 In Canada alone, the patient population using medical cannabis for various indications is growing at a pace of more than 10,000 new patients per month, and reached 201,398 in June 2017,2 a 268 per cent increase from the 75,166 registered at the end of June 2016.2
Across a growing number of jurisdictions, medical cannabis is being prescribed to help relieve chemotherapy-induced nausea and vomiting, as well as pain associated with cancer, and the management of chronic pain, arthritis and joint disorders, multiple sclerosis (MS), fibromyalgia and migraines.
Partnership with Liberty Health Sciences Inc. in Florida
Resolve’s deal with Aphria adds to a major partnership, announced on October 11th, with Liberty, an investor and operator in the medical cannabis market. Another important step in enhancing the medical cannabis patient experience, Liberty gains exclusive distribution rights to Resolve products within the state of Florida (subject to Florida Department of Health and Office of Medical Marijuana Use approvals). Adelson added: “These partnerships clearly signify our ambition to become a leader in the medical cannabis space throughout North America, leaving us in a great position for sustained growth.”
About Resolve Digital Health
Resolve Digital Health is positioned to be the leading provider of a metered dosing ecosystem for medical cannabis devices. The company’s proprietary technology, apps and cloud-based health information platform, found in Resolve’s debut product Breeze, address the numerous issues with currently available methods of cannabis delivery – establishing a standard of care and rigorous medical approach for the medical cannabis industry. With over three years of research and development, the complete product ecosystem will be initially available in select dispensaries in early 2018. For more information, visit: www.mybreeze.co or www.resolvedigitalhealth.com.
Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. www.aphria.com
About Liberty Health Sciences Inc.
Liberty Health Sciences Inc. (“Liberty”) is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal. Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near and mid-term opportunities. Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer. Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients. www.libertyhealthsciences.com
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.